Gail Lewis - Senior Principal Scientist - Technology, Translational Oncology

Gail Lewis

Senior Principal Scientist - Technology, Translational Oncology

"As a translational research scientist, I have the exciting and rewarding position of directing a lab that bridges basic science discoveries with early drug development in Oncology."
Years at Genentech
Publications at Genentech

I came to Genentech straight out of graduate school to join a lab working on anti-tumor cytokines (TNF-α and IFN-γ). We discovered that activated receptor tyrosine kinases, including HER2, were resistance mechanisms for TNF-α killing of tumor cells. These observations were coincident with the observation that overexpressed HER2 was oncogenic in preclinical models and was a poor prognostic marker in human breast cancer. We then focused our subsequent efforts on elucidating the biology of the HER2 pathway in breast cancer cells and on developing antibody-based therapeutics for HER2-positive cancers.

Featured Publication

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Clin Cancer Res. 2014 Jan 15;20(2):456-68.

Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.